ArticleVirchows Archiv : an international journal of pathology1995
Differential expression of beta 1, beta 3 and beta 4 integrins in sarcomas of the small, round, blue cell category.
Article in Virchows Archiv : an international journal of pathology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- The Extracellular Matrix in Soft Tissue Sarcomas: Pathobiology and Cellular Signalling.Frontiers in cell and developmental biology · 2021Review
- Triple-phaseMolecular and clinical oncology · 2017Article
- Clinical significance of the integrin α6β4 in human malignancies.Laboratory investigation; a journal of technical methods and pathology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Integrins are a large and complex family of membrane spanning alpha beta heterodimeric cell surface glycoproteins mediating cell/cell and cell/matrix interactions. Small, round, blue cell sarcomas (SRBCS) are a group of poorly differentiated tumours of various and in part uncertain histogenesis displaying similar cytomorphology. Among them are rhabdomyosarcomas (RMS), ganglioneuroblastomas [(G)NB], primitive peripheral neuroectodermal tumours (pPNET) and Ewing's sarcomas (ES). Thirty-two SRBCS were studied immunohistochemically for the distribution of beta 1, beta 3 and beta 4 integrins in situ. We found complex and to some extent differential patterns of beta 1, beta 3 and beta 4 integrin subunit expression in different types of SRBCS: all of the sarcomas studied were consistently beta 1+, beta 4-, alpha 2-. Four of nine RMS were completely negative for all other integrin subunits studied while one RMS was alpha 5+ throughout and three RMS were focally alpha 5+. Three RMS expressed the alpha 6 and alpha v chains. In contrast to RMS, pPNET and ES, all of which were alpha 1-, alpha 3-, (G)NB were alpha 3+ and frequently co-expressed alpha 1. The eight pPNET and seven ES studied showed a similarly restricted integrin profile that was limited to the expression of beta 1 and alpha 5 in nearly all cases. In summary, RMS were beta 1+, alpha 1-, alpha 3- and heterogeneously expressed alpha 5 and alpha 6. (G)NB were generally beta 1+, alpha 1+, alpha 3+, alpha 5-, alpha 6-. pPNET and ES were beta 1+, alpha 1-, alpha 3-, alpha 5+, alpha 6-. The data illustrate a complex expression pattern of various integrins in SRBCS, a differential expression pattern of some of the integrin subunits among different types of SRBCS and almost identical integrin profiles in pPNET and ES.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.